Search Result

Results for "

next-generation

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (2) Btk (2) CD20 (1) Fungal (2) HIV (2) HIV Protease (2) Influenza Virus (1) LPL Receptor (2) Parasite (1) PGE synthase (2) PI4K (1) ROS Kinase (2) Ser/Thr Protease (1) Trk Receptor (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Infection (6) Inflammation/Immunology (7) Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109121

Reldesemtiv CK-2127107	Others	Cardiovascular Disease
Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC₅₀ of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model .

HY-101977

Selitrectinib 3 Publications Verification LOXO-195	Trk Receptor	Cancer
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively .

HY-112684

RO-7

Influenza Virus Infection

RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.
HY-139564

DOTA Zoledronate

Others Cancer

DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .
HY-139998

PCSK9-IN-3

Ser/Thr Protease Cardiovascular Disease

PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitor.

RO-7	Influenza Virus	Infection
RO-7 is a next-generation polymerase (PA) endonuclease inhibitor of influenza A and B viruses.

DOTA Zoledronate	Others	Cancer
DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .

PCSK9-IN-3	Ser/Thr Protease	Cardiovascular Disease
PCSK9-IN-3 is a novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitor.

HY-108009

Rezafungin Biafungin; CD101; SP-3025	Fungal	Infection
Rezafungin (Biafungin) is a next-generation, broad-spectrum, and long-lasting echinocandin. Rezafungin shows potent antifungal activity against Candida spp., Aspergillus spp., and Pneumocystis spp. .

HY-108009A

Rezafungin acetate Biafungin acetate; CD101 acetate; SP-3025 acetate	Fungal	Infection
Rezafungin acetate (Biafungin acetate) is a next-generation, broad-spectrum, and long-lasting echinocandin. Rezafungin acetate shows potent antifungal activity against Candida spp., Aspergillus spp., and Pneumocystis spp. .

HY-132585A

SRP-5051 sodium Vesleteplirsen sodium	Others	Others
SRP-5051 sodium is a next-generation antisense oligonucleotide of peptide phosphorodiamidate morpholino oligomer (PPMO). SRP-5051 targeting exon 51 skipping in Duchenne muscular dystrophy (DMD) .

HY-112435

UCT943

PI4K Parasite Infection

UCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC₅₀ of 23 nM .

UCT943	PI4K Parasite	Infection
UCT943 is a next-generation Plasmodium falciparum PI4K inhibitor. UCT943 inhibits the P. vivax PI4K (PvPI4K) enzyme with an IC₅₀ of 23 nM .

HY-P99538

Ublituximab LFB-R603; TG-1101; TGTX-1101	CD20	Cancer
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .

HY-111021

ASP-4058 1 Publications Verification	LPL Receptor	Inflammation/Immunology
ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-111021A

ASP-4058 hydrochloride	LPL Receptor	Inflammation/Immunology
ASP-4058 hydrochloride is a next-generation, selective and orally active agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P₁ and S1P₅), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile .

HY-101977B

(3aR)-Selitrectinib (3aR)-LOXO-195	Trk Receptor	Cancer
(3aR)-Selitrectinib ((3aR)-LOXO-195) is an isform of Selitrectinib (HY-101977), which is a next-generation TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively .

HY-131003

Taletrectinib 1 Publications Verification DS-6051b; AB-106; IBI-344	ROS Kinase	Cancer
Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .

HY-141804

ER176

Others Neurological Disease

ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

ER176	Others	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

HY-131003A

Taletrectinib free base DS-6051b free base; AB-106 free base; IBI-344 free base	ROS Kinase	Cancer
Taletrectinib (DS-6051b) free base is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib free base potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC₅₀s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib free base also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants .

HY-132140

7-Deaza-7-propargylamino-3'-azidomethyl-dGTP	Biochemical Assay Reagents	Others
7-Deaza-7-propargylamino-3'-azidomethyl-dGTP is an analog of deoxyguanosine triphosphate (dGTP) that widely used in the next generation sequencing (NGS) .

HY-132139

7-Deaza-7-propargylamino-3'-azidomethyl-dATP	Biochemical Assay Reagents	Others
7-Deaza-7-propargylamino-3'-azidomethyl-dATP is an analog of deoxy adenosine triphosphate (dATP) that widely used in the next generation sequencing (NGS) .

HY-144237

BRP-201	PGE synthase	Inflammation/Immunology
Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the research of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC₅₀ value of 0.42 μM.

HY-144238

mPGES1-IN-6	PGE synthase	Inflammation/Immunology
MPGES-1 is considered as a promising therapeutic target of the next generation anti-inflammatory drugs in the research of inflammatory diseases. The < b > IC < sub > 50 < / sub > < / b > value of mPGES1-IN-6 is 0.03 μ M。

HY-131328A

(R)-Pirtobrutinib (R)-LOXO-305	Btk	Others
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations .

HY-17040

Darunavir Maximum Cited Publications 10 Publications Verification TMC114; UIC-94017	HIV HIV Protease	Infection Inflammation/Immunology
Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC₅₀ = 0.003 μM; IC₉₀ = 0.009 μM) with minimal cytotoxicity .

HY-131328

Pirtobrutinib 1 Publications Verification LOXO-305	Btk	Cancer
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM .

HY-112585

Darunavir-d9 TMC114-d9; UIC-94017-d9	HIV HIV Protease	Infection Inflammation/Immunology
Darunavir-d9 (TMC114-d9) is the deuterium labeled Darunavir. Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC₅₀ = 0.003 μM; IC₉₀ = 0.009 μM) with minimal cytotoxicity .

7-Deaza-7-propargylamino-3'-azidomethyl-dGTP	Gene Sequencing and Synthesis
7-Deaza-7-propargylamino-3'-azidomethyl-dGTP is an analog of deoxyguanosine triphosphate (dGTP) that widely used in the next generation sequencing (NGS) .

7-Deaza-7-propargylamino-3'-azidomethyl-dATP	Gene Sequencing and Synthesis
7-Deaza-7-propargylamino-3'-azidomethyl-dATP is an analog of deoxy adenosine triphosphate (dATP) that widely used in the next generation sequencing (NGS) .

CPN-219	Peptides	Inflammation/Immunology
CPN-219, a next-generation hexapeptidic NMUR2 agonist, achieves a dose-dependent and selective activation of NMUR2 with an EC₅₀ value of 2.2 nM .

Ublituximab LFB-R603; TG-1101; TGTX-1101	CD20	Cancer
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.